American Journal of Psychiatry · 1996 · 126 citations · 9 references
MedicineGeneticsPsychiatryPharmacogeneticsPharmacogenomicsPsychopharmacologyAntipsychotic PharmacologyAntipsychotic PharmacotherapyAntipsychotic TherapyPsychiatric GeneticsReceptor PolymorphismsSchizophrenia Spectrum DisordersAntipsychotic PharmacogenomicsPharmacogenomics Of Psychotropic DrugsPsychiatric GenomicsPsychiatric Rating ScalesReceptor PharmacogeneticsRestriction Fragment Length Polymorphism AnalysisSchizophrenia GeneticsSerotonin Receptor Polymorphisms
OBJECTIVE: The authors' goal was to determine whether either of two 5-HT2A receptor polymorphisms, 102-T/C and 452-His/Tyr, are associated with clozapine response. METHOD: Brief Psychiatric Rating Scale (BPRS) ratings were obtained in 70 patients with schizophrenia or schizoaffective disorder to determine their response to clozapine compared with a typical neuroleptic. Patients were genotyped with the polymerase chain reaction and restriction fragment length polymorphism analysis. RESULTS: Neither 102-T/C nor 452-His/Tyr was associated with clozapine response. There were no significant differences in BPRS scores among patients with different 5-HT2A genotypes at week 10 of clozapine administration. CONCLUSIONS: Allelic variation in the 5-HT2A gene is not associated with individual differences in clozapine response.
9
Clozapine for the Treatment-Resistant Schizophrenic
John M. Kane · Archives of General Psychiatry · 1988 · 4.1K citations
Medicine, Pharmacology, Psychiatry +16
An E-M algorithm and testing strategy for multiple-locus haplotypes.
Jeffrey C. Long, R C Williams, Margrit Urbanek · PubMed · 1995 · 535 citations